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Organophosphate poisoning
case with atypical clinical survey
and magnetic resonance imaging
findings
Organophosphorous compounds, the anti-
cholinesterases produce significant morbidity
and mortality. Although exact estimates are
not available, hospital based statistics suggest
that nearly half of the admissions to emer-
gency with acute poisoning are attributable
to organophosphates.1 Sahin et al reported an
organophosphate poisoning proportion of
15.1% among 564 poisonings.2 Patients with
organic insecticide poisoning present with a
spectrum of manifestations ranging from
gastrointestinal symptoms of nausea, vomit-
ing, and diarrhoea to severe neurological
manifestations of fasciculations, seizures,
and neuromuscular weakness and paralysis
or cardiac manifestations of arrhythmias and
conduction disturbances.3 The overall mor-
tality was reported as 18%.4
We report a case with atypical neurological
findings and magnetic resonance imaging
(MRI) lesions attributable to organopho-
sphate poisoning.
A previously healthy 31 year old man from
Denizli (Turkey) presented with sudden
onset of nausea, vomiting, and loss of con-
scious. During four days before the onset of
his symptoms he was more irritable than
usual. Five hours before his admission nausea
and vomiting had begun after he ate royal jelly
and he lost his conscious progressively.
He was sterile and he was informed of the
diagnosis of asospermia on the day when he
was intoxicated. His family history was
unremarkable.
While he was admitted to the intensive
care unit he was unconscious, his blood pres-
sure was measured at 110/70 mm Hg, and
heart rate was 62/minute. His body tempara-
ture was 39 C̊. His eyes were open but he was
not looking meaningful. He was in a decere-
brate posture. His pupils were bilaterally
myotic and his left eye was deviated to inte-
rior and down at primary position. Babinsky
sign was bilaterally positive. Deep tendon
reflexes were overactive at his lower extre-
mities. Tracheal secretion was increased.
Laboratory studies were unremarkable
except for white blood cell of 20 900 K/ml.
Pseuodocholinesterase activity was 1860
(normal range: 3500–8500) on the first day,
890 on the second day, and 860 on the third
day. CSF examination was normal. Blood and
urine toxicological investigation showed that
he was intoxicated with thyiometane and
fenpropothine (insecticides) and also a high
concentration of paracetamol was found in
his gastric fluid examination. His cranial
computed tomography scan showed a
subarachnoid cyst at the posterior fossa
and there was no pathological contrast
enhancing. MRI showed hyperintense
lesions at T2W images at the level of
mesencephalone and cerebellum. On the
third day, a second MRI showed that the
mesencephalic and cerebellar lesions were
enlarged (fig 1).
As we could not exclude the diagnosis of
herpes encephalitis, he was given antiviral
therapy. He was also treated with the
antidotes atropine and pralidoxime, decreas-
ing consciousness necessitated intubation,
mechanical ventilation, and other suppor-
tive measures but his clinical progression
worsened and he died after a severe ventri-
cular arrhythmia resulting with cardiac
arrest.
Comment
The acute muscarinic and nicotinic side
effects of organophosphate poisoning are
well known. After accidental or suicidal
exposure, anticholinesterases lead to three
well defined neurological syndromes—that
is, initial life threatening acute cholinergic
crisis, which often requires management in
intensive care unit, intermediate syndrome in
which cranial nerve palsies, proximal muscle
weakness, and respiratory muscle weakness
are common and patients often require
respiratory support, and delayed organopho-
sphate induced polyneuropathy.1
Our patient did not show these well
defined neurological syndromes. However,
decerebrate posture and eye deviation indi-
cated a broad brain stem lesion. In the first
hours he was not unconscious and obeying
orders occasionally. Normal EEG findings
supported that there was not a serious
cortical involvement. This is a rare clinical
status and only Hollis et al have reported two
cases of organophosphate poisoning misdiag-
nosed as having brain stem stroke.5
Yilmazlar et al reported perfusion defects in
brain single photon emission computed
tomography particularly in the parietal lobe
of patients with organophosphate poisoning6
and Wang et al reported that photon emission
computed tomography analysis may be help-
ful in estimating the metabolic deficit of
visual cortex and in establishing the organic
nature of cortical visual loss in acute orga-
nophosphorous poisoning cases.7 However,
well localising MRI findings attributable to
organophosphate poisoning have not been
previously reported.
Hyperintense lesions in T2W images may
be seen in viral encephalitis and other
subacute brain stem infections but this was
not the case because toxic agents had been
fixed and clinical findings worsened despite
antiviral therapy. Another clue for organo-
phosphate intoxication of the patient was
typical reversible cholinergic signs with atro-
pine administration such as improving bra-
dycardia.
We report on this patient because of
atypical clinical survey, MRI findings, and
well localised lesion at the early period of
toxication.
E Teke
Neurology Department, Pamukkale University,
Denizli, Turkey
Figure 1 (A) First MRI T2W image, cerebellum; (B) first MRI T2W image, mesencephalon;
(C) second MRI T2W image, cerebellum; (D) second MRI T2W image, mesencephalon.
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Coincidence of a large SCA12
repeat allele with a case of
Creutzfeld-Jacob disease
The spinocerebellar ataxias (SCAs) are a
group of autosomal dominant inherited
neurodegenerative disorders characterised
by progressive cerebellar dysfunction. Besides
cerebellar manifestations a variety of asso-
ciated neurological signs, such as ophthal-
moplegia, dementia, or pyramidal and
extrapyramidal signs may occur. At least 21
loci for SCAs including 11 different genes
have been identified. SCA 1, 2, 3, 6, 7, and 17
are caused by expansion of a translated CAG
repeat in the corresponding gene leading to
an expanded polyglutamine tract in the
translated protein. In contrast, Holmes and
colleagues1 recently described a large pedi-
gree with a new form of autosomal dominant
ataxia (SCA12) associated with an expanded
CAG tract in the 59 untranslated region of the
gene PPP2R2B, encoding a brain specific
regulatory subunit of protein phosphatase
PP2A. Clinical findings in SCA12 patients
include upper extremity tremor, cerebellar
signs and late onset dementia.2
We report on a patient with Creutzfeld-
Jakob disease (CJD) carrying a 49 CAG repeat
at the SCA12 locus. Additionally, we analysed
a large sample of sporadic and hereditary
ataxia patients for SCA12 mutations.
A 57 year old man of German origin pre-
sented subacutely with gait ataxia and a
striking action tremor. Shortly after disease
onset, his wife also noticed dysarthria. There
was no evidence for neurological diseases in
his family. His father died at 43 years from
cardiac infarction, his 80 year old mother has
no other children. On neurological examina-
tion, he showed no signs of cognitive impair-
ment, oculomotor performance was normal.
Deep tendon reflexes were depressed, there
were no paresis, no pathological signs, and
sensory testing was normal for pain, tem-
perature, and touch. His gait was severely
ataxic, there was a moderate dysmetria of the
upper and lower limbs with a prominent
action tremor.
An initial brain MRI was normal. Extensive
blood tests including vitamins B12 and E,
paraneoplastic antibodies and serum cerulo-
plasmin showed no pathological results. His
cerebrospinal fluid was normal, except for a
moderately raised protein level.
Electrophysiology showed subclinical sen-
sory motor neuropathy. A genetic analysis of
SCAs revealed a repeat expansion of 49 CAGs
in the PPP2R2B gene for SCA12.
The disease rapidly progressed and after
four months the patient additionally devel-
oped dementia with disorientation and para-
noid hallucinations together with a
deterioration of his neurological status espe-
cially for the ability to coordinate his move-
ments. A second MRI scan now showed
bilateral signal hyperintensity in the putamen
and caudate nucleus, as well as the frontal,
parietal, and insular cortices. EEG showed
slowing of background activity with bursts of
generalised h rhythm. Additionally, CSF was
positive for 14.3.3 protein leading to the
assumption of a probable CJD case.
The patient died two months later because
of aspiration pneumonia. Necropsy revealed
a brain of 1265 g, which appeared to be
unaffected macroscopically. Histological inves-
tigations showed moderate to severe spongi-
form changes with confluent vacuoles, a mild
to moderate astrocytic gliosis, and a moderate
nerve cell loss in the cerebral neocortex and, to
a variable extent, in the basal ganglia, thala-
mic nuclei, and midbrain structures. The hip-
pocampal formation and brain stem nuclei
were comparatively free of pathological
changes. Spongiform changes were seen also
in the molecular layer of the cerebellum toge-
ther with a granule cell loss. Kuru plaques
could be detected next to Purkinje cells as a
hallmark of this special subtype of CJD.3 With
a monoclonal antibody against prion protein
(Gö138), perivacuolar prion protein deposits
were detectable in cortical areas and plaque-
like or granular deposits in the cerebellum.
Genetic analysis of the PRNP gene revealed
the MV genotype at codon 129.
Additionally, we screened 1028 patients
from northern Germany with cerebellar
ataxia, including 113 patients with positive
family history, and 150 healthy controls for
SCA12 mutation.
Repeat expansions in all other known SCA
genes had been previously excluded.
SCA12 expansions larger than 50 repeats
were not detected in any of the patients
or controls. In addition to the CJD patient
with 49 CAG repeats, alleles of 40 respec-
tively 41 repeats were found in two patients
with late onset sporadic ataxia. All other
allele sizes ranged from 4 to 28 CAG repeats
with a heterozygosity of 60.7% as shown in
table 1. The most common allele containing
10 CAG repeats was found in 61.7% of all
chromosomes.
Comment
SCA12 is a very rare entity for autosomal
dominant and sporadic ataxias with only six
Indian and one American pedigree of German
descent published at present.2 4 5 The
expanded alleles ranged from 55 to 78 CAG
repeats, whereas normal alleles ranged from
7–31 repeats. Recently, an allele of even 45
repeats was described in an Indian control
subject without any neurological symptoms
and with no family history of ataxia.5 We
now present a case of CJD bearing a repeat of
49 CAG copies. The initial symptoms of this
patient resembled those described in SCA12
patients. In particular the action tremor in
combination with cerebellar signs that pre-
ceded the cognitive impairment for four
Table 1 Distribution of alleles at the SCA12 locus among 1029 ataxia patients
and 150 healthy controls. Undetected repeat lengths are not shown
Healthy controls Ataxia patients
(CAG)n Number Frequency (%) Number Frequency (%)
4 – – 2 0.10
7 1 0.33 1 0.05
9 2 0.67 49 2.38
10 176 58.67 1270 61.71
11 3 1.00 20 0.97
12 1 0.33 3 0.15
13 34 11.33 229 11.13
14 33 11.00 174 8.45
15 37 12.33 244 11.86
16 1 0.33 20 0.97
17 4 1.33 19 0.92
18 – – 14 0.68
19 1 0.33 2 0.10
20 1 0.33 2 0.10
21 5 1.67 – –
22 – – 1 0.05
23 – – 1 0.05
24 1 0.33 1 0.05
26 – – 1 0.05
28 – – 2 0.10
40 – – 1 0.05
41 – – 1 0.05
49 – – 1 0.05





















months was striking. On the other hand,
ataxia is also a prominent clinical feature of
the Kuru-plaque variant found in this
patient, which is linked to the MV genotype
at codon 129 and PRPsc type 2. However, we
cannot elucidate whether CJD of this patient
unmasked SCA12 at a subclinical stage or
whether the 49 allele is a large and rare
normal allele without any influence on the
phenotype and, unfortunately, there are no
other family members available for genetic
evaluation. What remains is the coincidence
of two very rare diseases, respectively genetic
variations. The protein phophatase PP2A may
play a part in tau phosphorylation and
apoptosis. Therefore, the possibility that a
large SCA12 repeat could influence the
pathogenesis of sporadic CJD, especially the
Kuru-plaques variant, should be further
evaluated.
The role of the 40 and 41 CAG repeats in
two sporadic late onset ataxia cases is also
difficult to interpret and we cannot exclude a
pathogenic influence, although an even
larger allele was found in a young Indian
healthy control. The findings of this study
implicate a more sophisticated interpretation
of SCA12 alleles and raise the question about
the diagnostic threshold between normal and
expanded alleles.
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Germany
W Schulz-Schaeffer
Department of Neuropathology, University of
Göttingen, Germany
Y Hellenbroich, M F Nitschke
Department of Neurology, University of Lübeck
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Pre-treatment with
corticosteroids and a single cycle
of high dose albendazole for
subarachnoidal cysticercosis
Cysticercosis is a common parasitic disease of
the central nervous system and a pleo-
morphic neurological disorder. It is an ende-
mic problem in developing countries and is
now increasing in industrialised nations.1 In
Mexico neurocysticercosis is one of the main
reasons for neurological consultation, and the
first cause of epilepsy in adults.2 The treat-
ment of neurocysticercosis is controversial
and depends on the clinical and neuroima-
ging features, as well as the extent and
severity of the associated inflammatory reac-
tion.3 Basal subarachnoidal cysticercosis and
racemose disease of sylvian fissure may
behave aggressively producing intracranial
hypertension, obstructive hydrocephalus,
chronic arachnoiditis, vasculitis, and cerebral
infarctions.4 Subarachnoidal cysticercosis
may have a chronic course and a poor
prognosis, and is still treated surgically. In a
recent open trial of 33 patients with subar-
achnoidal cysts of at least 50 mm in dia-
meter, treatment with albendazole at a dose
of 15 mg/kg/day during 28 days produced an
adequate response in 12 patients (36%). The
remaining 21 patients (64%) required
repeated courses of albendazole and 10
treatments with praziquantel because of a
partial or incomplete response to the first
albendazole cycle.5 Repeated treatments are
not a minor problem in areas where cysti-
cercosis is endemic and medical resources are
limited. To explore a more effective regimen
for subarachnoidal cysticercosis we started a
pilot study in 1998 with corticosteroids pre-
treatment and a single course of a higher
albendazole dose.
We included 12 patients with the diagnosis
of subarachnoidal cysticercosis based in
clinical data, imaging studies, and inflamma-
tory cerebrospinal fluid with a positive
enzyme linked immunosorbent assay
(ELISA) test against cysticercal antigens.
After written informed consent six hospita-
lised patients were pre-treated with intrave-
nous dexamethasone at a dose of 8 mg every
eight hours for five days. Four outpatients
not receiving corticosteroids were given oral
prednisone at dose of 1.5 mg/kg of body
weight per day for five days. Two patients
with severe arachnoiditis with incomplete
response to prednisone, one of them with
vasculitis proved by angiography were
already receiving cyclophosphamide 100 mg
per day, the drug was continued in both and
one of them was also pre-treated with oral
prednisone as above.
Albendazole was given at a dose of 30 mg/
kg of body weight per day in three divided
doses for 15 days. As soon as oral intake was
tolerated patients taking dexamethasone
were switched to prednisone at dose of
1 mg/kg of body weight a day. After four
weeks, and depending on the clinical status
prednisone dose was tapered individually.
Magnetic resonance imaging (MRI) was
performed before treatment and three to six
months after treatment.
Four men and eight women with an
average age of 32.8 years (range 20 to 47)
were included. The mean hospital stay for
inpatients was 17 days. Table 1 gives symp-
toms and signs before treatment and at the
end of the 15 days of albendazole treatment.
In five patients a ventriculoperitoneal shunt
was placed before albendazole treatment. In
seven patients, corticosteroids improved clin-
ical manifestations within the first 24 hours.
On baseline MRI, the number of subar-
achnoid cysts varied from 1 to 24 cysts per
patient; 10 patients had cysts in the basal
cisterns and three had racemose cysts in
Sylvian fissure. In three patients additional
lobar and subcortical cysts were also present
and ependymal or leptomeningeal enhance-
ment was observed in five patients.
On MRI studies at six months of follow up
a reduction of 86% of the number of the
subarachnoidal vesicles was observed,
decreasing from 73 to 10 cysts (p = 0.02;
Mann-Whitney U test two tailed), with a
Table 1 Changes after treatment in neurological symptoms, signs, and
cerebrospinal fluid (CSF) analysis
Before
treatment
After 15 days of corticosteroids and
albendazole treatment
Symptoms Number Number p
Value*
Headache 11 7 0.115
Nausea 8 2 0.036
Vomiting 7 1 0.027
Blurred vision 3 1 0.590
Somnolence 3 0 0.217
Abnormal mental status 3 1 0.590
Seizures 3 1 0.590
Diplopia 3 0 0.478
Signs
Intracranial hypertension 11 2 0.001
Papilloedema 10 3 0.012
Abnormal ocular movements 3 0 0.217
Incoordination 2 1 1.000
Motor deficit 1 0 1.000
CSF Before
treatment
At six month follow up
Opening pressure mean (SD) 236 (130) 159 (37) 0.018
Glucose mean (SD) 62 (39) 45 (15) 0.119
Proteins mean (SD) 73 (94) 97 (117) 0.564
Cells mean (SD) 70 (133) 59 (110) 0.998
ELISA+cysticercus antigens 9 12 0.590
*Univariate analysis by Fisher’s exact test. Mann-Whitney U test, two tailed.





















volume reduction of 80%. Eight patients had
satisfactory clinical recovery and four
patients presented minor neurological deficit
with functional independence.
During treatment one patient required
ventriculoperitoneal shunt revision for acute
intracranial hypertension. In the remaining
patients the observed adverse effects were
headache and nausea in two who did not
required drug withdrawal.
Significant changes after treatment were
observed mainly in symptoms and signs of
intracranial hypertension and these were
attributable to corticosteroid effects or shunt-
ing, or both. No significant modifications of
glucose cells and protein levels of CSF were
observed during six months of follow up. This
means that chronic aracnoiditis continues
after cyst destruction, and for some patients
corticosteroids are necessary for long term
treatment. We base our dose reductions
according to clinical parameters, CSF char-
acteristics, and leptomeningeal enhancement
(MRI). In this study ELISA test’s sensitivity
increased after treatment.
Pre-treatment with corticosteroids reduces
the risk of complications secondary to
destruction of cysticerci.4–5 In our patients
an immediate clinical improvement seemed
to be an indicator of adequate tolerance to
subsequent albendazole treatment. Because
of the variability of albendazole pharmacoki-
netics, we considered that treatment with
30 mg/kg/day of albendazole will increase its
concentration in plasma and CSF, improving
the efficacy. This small series shows that a
higher albendazole dose along with cortico-
steroid treatment was safe and useful in the
treatment of subarachnoidal cysticercosis.
Patients need to be carefully selected and
require close observation and to be available
for long term follow up. A randomised trial of
standard compared with high albendazole
dose is in progress at our centre.
C Márquez-Caraveo, F Góngora-Rivera,
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Short term benefit of battery
depletion in vagus nerve
stimulation for epilepsy
Interest in neurostimulation to treat epilepsy
has rekindled over the past decade, with
vagus nerve stimulation (VNS) now an
accepted part of the algorithm for care of
patients with medically refractory epilepsy.1
More than 15 000 VNS devices have been
surgically implanted in patients around the
world. The reported improvements in seizure
control are modest and the mechanism by
which VNS may exert its effects is unclear,
however, the benefits are presumed to be
directly related somehow to the electrical
stimulation applied to the nerve. A small
number of relevant experimental studies
have shown antiepileptic effects related to
VNS, although the effects may be non-
specific, for example, in rats heating of the
tail is equally effective as stimulation of the
vagus nerve in stopping seizures and decreas-
ing interictal spikes.2 In our own work with
thalamic deep brain stimulation for epilepsy
we found that the observed benefits in
patients’ seizure control bore no relation to
whether the stimulators were actually turned
on or not.3 Because patients can sense active
VNS in the form of laryngeal side effects, no
similar sham stimulation placebo has been
possible with VNS.
If stimulation of the vagus nerve is actually
a necessary part of VNS for epilepsy, deple-
tion of the stimulator battery would be
expected to result in an increase in seizures.
Indeed, status epilepticus was recently
reported to have occurred in one patient after
stopping VNS for an elective brain MRI
scan.4
No study has been formally published
describing the effects of battery depletion in
a large group of patients treated with VNS for
epilepsy, however, the data from just such a
study have been published informally—in the
Cyberonics VNS Physician’s Manual.5 It is of
interest to examine these data. Over the
course of follow up of patients in the E03
VNS trial,6 a total of 72 battery depletions in
68 patients occurred. Seizure frequency after
battery depletion was monitored for one to
four weeks after stimulation was stopped,
with the outcome results divided into three
groups: patients having a greater than 25%
increase in seizures, patients unchanged with
a less than 25% increase or decrease in
seizures, and patients with a greater than
25% decrease in seizures. Forty two of 72
cases (58%) were in the last group—that is,
the large majority of patients improved after
battery depletion. Nineteen of 72 cases (26%)
were unchanged and 11 of 72 (15%) wor-
sened.
A x2 analysis of the results comparing
patients with a greater than 25% seizure
reduction with patients with a greater than
25% increase in seizures after battery deple-
tion shows a highly significant benefit to
battery failure (p,0.0001; x2 = 18.14, two
tailed test). This is the most significant
finding of any statistical analysis performed
in all of the VNS studies used to support
licensing of the device as a treatment for
epilepsy.5–7 As the research hypothesis here
specifies the direction in which a change will
occur—that is, ‘‘there will be an increase in
seizures when VNS stops,’’ the alternative
hypothesis is actually one tailed, which
makes the significance of the findings even
greater (p,0.00005). This means that the
probability that the observed findings of
improvement with battery depletion in most
patients could have occurred by chance is less
than 1 in 20 000. It is possible that the
findings do represent such a chance occur-
rence. It is equally possible, or perhaps more
probable, that any sort of non-specific change
in patients with epilepsy might provide a
perturbation sufficient to effect improve-
ments in seizure control, at least in the short
term. Either way, benefits in seizure control
with VNS in humans seem to have little
specific to do with active stimulation of the
vagus nerve.
R Wennberg
Krembil Neuroscience Centre, Toronto Western
Hospital, University of Toronto, 399 Bathurst Street,
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